After implantation of a mechanical cardiac valve, lifelong, full antic
oagulation has been the tradition. After implantation of a biological
valve, anticoagulation during 3 months subsequent to the operation is
customary. This review evaluates the role of platelet inhibition after
cardiac valve replacement. Platelet aggregation is inhibited effectiv
ely by aspirin in a daily dose of 100 - 160 mg. At this dose, episodes
of severe bleeding are not significantly more frequent than during pl
acebo, whereas patients on full anticoagulation bleed at a rate of 2%
per year. After implantation of a mechanical cardiac valve, sole plate
let inhibition is inferior to full anticoagulation. With a lower rate
of bleeding, aspirin appears to prevent thromboembolic episodes caused
by mechanical bileaflet prostheses (e.g., St. Jude) in the aortic pos
ition, and is almost as efficient as full anticoagulation. In Germany,
patients with a porcine bioprosthesis, as currently in use, in the ao
rtic position, frequently receive 100 mg aspirin per day. For patients
with porcine bioprostheses in the mitral plus eventually in the aorti
c position in stable sinus rhythm, 100 mg aspirin per day is preferred
to anticoagulation. For children with mechanical aortic valves, aspir
in (2 mg/kg/day) needs to be considered an effective and convenient al
ternative to anticoagulation. Combining anticoagulation with 100 mg as
pirin per day after implantation of a left-sided mechanical cardiac va
lve is pathophysiologically sound, but used to be considered as render
ing the patients too bleeding-prone. Recently, total mortality and mor
bidity definitely have been demonstrated to be reduced by combined ant
icoagulation and platelet inhibition as compared to sole anticoagulati
on. Combining platelet inhibition with moderate anticoagulation (INR 2
.0 - 3.0) was superior to combining it with full anticoagulation in te
rms of safety (INR > 3.0). Thus, current evidence favors combining mod
erate anticoagulation with 100 mg aspirin per day after left-sided mec
hanical cardiac valve replacement.